Engineered RVG-exosomes-mediated delivery of siRNAs targeting NMDAR alleviates orofacial neuropathic pain by suppressing central sensitivity

Quick Facts

  • Publication title: Engineered RVG-exosomes-mediated delivery of siRNAs targeting NMDAR alleviates orofacial neuropathic pain by suppressing central sensitivity
  • Journal: J Pain
  • Year: 2025
  • DOI: 10.1016/j.jpain.2025.105457
  • PMID/PMCID: 40482847

Research overview

Taken together, our study investigated the role of NR2A/B in central nociceptive sensitization and suggested that RVG-EXOs-mediated delivery of siRNAs targeting NR2A and NR2B was effective for orofacial NP treatment. Engineered exosomes have great potential as drug delivery systems for treating diseases.

Key findings

Orofacial neuropathic pain (NP) is a common complication in oral clinical practice that severely affects quality of life.

However, NP does not currently receive effective medications.

Engineered exosomes have great potential as drug delivery systems for treating diseases.

Here, patch clamp techniques showed that the deficiency of N-methyl-D-aspartic acid receptor (NMDAR) subunits 2A and 2B reversed the spontaneous excitatory postsynaptic current (sEPSC) frequency and neuronal excitability in the spinal trigeminal nucleus caudalis (SpVc) after injury, which is an effective therapeutic target for NP.

Echo Biotech Role

Echo Biotech contributed cargo loading, targeting-peptide/surface modification, EV material/reference-material supply; the study also used or cited ExoLoad®, ExoBrooch™, ContrExo®.

Related platforms: Echosome®, EV Materials / Reference Materials, Research Reagents & Tools

Related services and capabilities: Small RNA / Cargo Loading, Targeting Peptide / Surface Modification, EV Material / Reference Material Supply

Related products or reagents: ExoLoad® Nucleic Acid Loading Kit, ExoBrooch™ Targeting Peptide/Lipid Anchor Kit, ContrExo® EV Reference Material

References

Original publication: Engineered RVG-exosomes-mediated delivery of siRNAs targeting NMDAR alleviates orofacial neuropathic pain by suppressing central sensitivity The journal of pain. 2025. DOI: 10.1016/j.jpain.2025.105457. PMID/PMCID: 40482847.